These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 37402345)

  • 1. Clinical features of MOGAD with brainstem involvement in the initial attack versus NMOSD and MS.
    Xu Q; Yang X; Qiu Z; Li D; Wang H; Ye H; Jiao L; Zhang J; Di L; Lei P; Dong H; Liu Z
    Mult Scler Relat Disord; 2023 Sep; 77():104797. PubMed ID: 37402345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression independent of relapses in aquaporin4-IgG-seropositive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, and multiple sclerosis.
    Molazadeh N; Akaishi T; Bose G; Nishiyama S; Chitnis T; Levy M
    Mult Scler Relat Disord; 2023 Dec; 80():105093. PubMed ID: 37949025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS.
    Banks SA; Morris PP; Chen JJ; Pittock SJ; Sechi E; Kunchok A; Tillema JM; Fryer JP; Weinshenker BG; Krecke KN; Lopez-Chiriboga AS; Nguyen A; Greenwood TM; Lucchinetti CF; Zalewski NL; Messina SA; Flanagan EP
    J Neurol Neurosurg Psychiatry; 2020 Dec; ():. PubMed ID: 33372052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumefactive Demyelination in MOG Ab-Associated Disease, Multiple Sclerosis, and AQP-4-IgG-Positive Neuromyelitis Optica Spectrum Disorder.
    Cacciaguerra L; Morris P; Tobin WO; Chen JJ; Banks SA; Elsbernd P; Redenbaugh V; Tillema JM; Montini F; Sechi E; Lopez-Chiriboga AS; Zalewski N; Guo Y; Rocca MA; Filippi M; Pittock SJ; Lucchinetti CF; Flanagan EP
    Neurology; 2023 Mar; 100(13):e1418-e1432. PubMed ID: 36690455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: Brainstem involvement - frequency, presentation and outcome.
    Jarius S; Kleiter I; Ruprecht K; Asgari N; Pitarokoili K; Borisow N; Hümmert MW; Trebst C; Pache F; Winkelmann A; Beume LA; Ringelstein M; Stich O; Aktas O; Korporal-Kuhnke M; Schwarz A; Lukas C; Haas J; Fechner K; Buttmann M; Bellmann-Strobl J; Zimmermann H; Brandt AU; Franciotta D; Schanda K; Paul F; Reindl M; Wildemann B;
    J Neuroinflammation; 2016 Nov; 13(1):281. PubMed ID: 27802825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-MOG associated disorder-Clinical and radiological characteristics compared to AQP4-IgG+ NMOSD-A single-center experience.
    Rempe T; Tarhan B; Rodriguez E; Viswanathan VT; Gyang TV; Carlson A; Tuna IS; Rees J
    Mult Scler Relat Disord; 2021 Feb; 48():102718. PubMed ID: 33388560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder and MOG Antibody Disease.
    Barreras P; Vasileiou ES; Filippatou AG; Fitzgerald KC; Levy M; Pardo CA; Newsome SD; Mowry EM; Calabresi PA; Sotirchos ES
    Neurology; 2022 Nov; 99(22):e2504-e2516. PubMed ID: 36240094
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leptomeningeal Enhancement in Pediatric Anti-Myelin Oligodendrocyte Glycoprotein Antibody Disease, Multiple Sclerosis, and Neuromyelitis Optica Spectrum Disorder.
    Goldman-Yassen A; Lee A; Gombolay G
    Pediatr Neurol; 2024 Apr; 153():125-130. PubMed ID: 38382244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of New Silent MRI Lesions in Myelin Oligodendrocyte Glycoprotein Antibody Disease and Aquaporin-4 Antibody Neuromyelitis Optica Spectrum Disorder.
    Camera V; Holm-Mercer L; Ali AAH; Messina S; Horvat T; Kuker W; Leite MI; Palace J
    JAMA Netw Open; 2021 Dec; 4(12):e2137833. PubMed ID: 34878547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic implications of MOG-IgG detection in sera and cerebrospinal fluids.
    Matsumoto Y; Kaneko K; Takahashi T; Takai Y; Namatame C; Kuroda H; Misu T; Fujihara K; Aoki M
    Brain; 2023 Sep; 146(9):3938-3948. PubMed ID: 37061817
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicoradiological comparative study of Aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorder (NMOSD) and MOG antibody associated disease (MOGAD): A prospective observational study and review of literature.
    Nagireddy RBR; Kumar A; Singh VK; Prasad R; Pathak A; Chaurasia RN; Mishra VN; Joshi D
    J Neuroimmunol; 2021 Dec; 361():577742. PubMed ID: 34655992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiated pattern of complement system activation between MOG-IgG-associated disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder.
    Cho EB; Min JH; Waters P; Jeon M; Ju ES; Kim HJ; Kim SH; Shin HY; Kang SY; Lim YM; Oh SY; Lee HL; Sohn E; Lee SS; Oh J; Kim S; Huh SY; Cho JY; Seok JM; Kim BJ; Kim BJ
    Front Immunol; 2024; 15():1320094. PubMed ID: 38576611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of MRI T2-lesion evolution in pediatric MOGAD, NMOSD, and MS.
    Redenbaugh V; Chia NH; Cacciaguerra L; McCombe JA; Tillema JM; Chen JJ; Lopez Chiriboga AS; Sechi E; Hacohen Y; Pittock SJ; Flanagan EP
    Mult Scler; 2023 Jun; 29(7):799-808. PubMed ID: 37218499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint radiomics and spatial distribution model for MRI-based discrimination of multiple sclerosis, neuromyelitis optica spectrum disorder, and myelin-oligodendrocyte-glycoprotein-IgG-associated disorder.
    Luo X; Li H; Xia W; Quan C; ZhangBao J; Tan H; Wang N; Bao Y; Geng D; Li Y; Yang L
    Eur Radiol; 2024 Jul; 34(7):4364-4375. PubMed ID: 38127076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased peripheral inflammatory responses in myelin oligodendrocyte glycoprotein associated disease and aquaporin-4 antibody positive neuromyelitis optica spectrum disorder.
    Bauer A; Rudzki D; Berek K; Dinoto A; Lechner C; Wendel EM; Hegen H; Deisenhammer F; Berger T; Höftberger R; Rostasy K; Mariotto S; Reindl M
    Front Immunol; 2022; 13():1037812. PubMed ID: 36451827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD.
    Redenbaugh V; Flanagan EP
    Neurotherapeutics; 2022 Apr; 19(3):808-822. PubMed ID: 35267170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS.
    Duan Y; Zhuo Z; Li H; Tian DC; Li Y; Yang L; Gao C; Zhang T; Zhang X; Shi FD; Barkhof F; Liu Y
    J Neurol Neurosurg Psychiatry; 2021 Jul; 92(7):709-716. PubMed ID: 33687975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obesity is associated with myelin oligodendrocyte glycoprotein antibody-associated disease in acute optic neuritis.
    Stiebel-Kalish H; Rubarth K; Shouchane-Blum K; Tiosano A; Lotan I; Hellmann MA; Wilf-Yarkoni A; Bialer O; Flanagan EP; Pittock SJ; Bhatti MT; Schmitz-Hübsch T; Paul F; Asseyer S; Chen JJ
    Sci Rep; 2022 Dec; 12(1):21312. PubMed ID: 36494385
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to Disability Milestones and Annualized Relapse Rates in NMOSD and MOGAD.
    Duchow A; Bellmann-Strobl J; Friede T; Aktas O; Angstwurm K; Ayzenberg I; Berthele A; Dawin E; Engels D; Fischer K; Flaskamp M; Giglhuber K; Grothe M; Havla J; Hümmert MW; Jarius S; Kaste M; Kern P; Kleiter I; Klotz L; Korporal-Kuhnke M; Kraemer M; Krumbholz M; Kümpfel T; Lohmann L; Ringelstein M; Rommer P; Schindler P; Schubert C; Schwake C; Senel M; Then Bergh F; Tkachenko D; Tumani H; Trebst C; Vardakas I; Walter A; Warnke C; Weber MS; Wickel J; Wildemann B; Winkelmann A; Paul F; Stellmann JP; Häußler V;
    Ann Neurol; 2024 Apr; 95(4):720-732. PubMed ID: 38086777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The distinction of area postrema syndrome between MOGAD and NMOSD.
    Chen Y; Zhangbao J; Xu J; Zhou L; Zhou Z; Quan C
    Heliyon; 2024 May; 10(10):e30633. PubMed ID: 38779012
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.